Phase II Clinical Trial of Camrelizumab Combined with AVD (Epirubicin, Vincristine and Dacarbazine) in the First-Line Treatment for Patients with Advanced Classical Hodgkin's Lymphoma

被引：3
|
作者：
Zhao, Shuang [1 ]
Liu, Yanyan [1 ]
Yao, Zhihua [2 ]
Yan, Zheng [3 ]
Yao, Shuna [1 ]
Chu, Junfeng [1 ]
Wang, Haiying [1 ]
Zhang, Jiuyang [1 ]
Zhang, Peipei [1 ]
Zhou, Wenping [1 ]
机构：
[1] Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[2] Zhengzhou Univ, Dept Internal Med, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[3] Zhengzhou Univ, Internal Med, Affiliated Canc Hosp, Zhengzhou, Peoples R China
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-166829
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：6579 / 6580
页数：2
相关论文
共 50 条
  • [1] Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma
    Zhang, Bo
    Qi, Ling
    Wang, Xi
    Xu, Jianping
    Liu, Yun
    Mu, Lan
    Wang, Xingyuan
    Bai, Lidan
    Huang, Jing
    CANCER COMMUNICATIONS, 2020, 40 (12) : 711 - 720
  • [2] Fertility and Gonadal Function after First-Line Treatment with Nivolumab-AVD in Hodgkin Lymphoma Patients: An Analysis from the Phase II GHSG Nivahl Trial
    Broeckelmann, Paul J.
    Buehnen, Ina
    Herhaus, Peter
    Meissner, Julia
    Trautmann-Grill, Karolin
    Mueller, Horst
    Fuchs, Michael
    von Tresckow, Bastian
    Borchmann, Peter
    Engert, Andreas
    Behringer, Karolin
    BLOOD, 2023, 142
  • [3] Quality of Life with Nivolumab and AVD First-Line Treatment in Hodgkin Lymphoma: Patient-Reported Outcomes from the Phase II GHSG Nivahl Trial
    Broeckelmann, Paul J.
    Buehnen, Ina
    Herhaus, Peter
    Meissner, Julia
    Trautmann-Grill, Karolin
    Mueller, Horst
    Fuchs, Michael
    von Tresckow, Bastian
    Borchmann, Peter
    Engert, Andreas
    Behringer, Karolin
    BLOOD, 2023, 142
  • [4] PHASE-II STUDY OF ORCHIECTOMY COMBINED WITH EPIRUBICIN AS FIRST-LINE TREATMENT IN ADVANCED PROSTATE CARCINOMA
    LELIEFELD, H
    WILS, J
    PEULEN, G
    SMEETS, J
    CANCER INVESTIGATION, 1994, 12 (04) : 395 - 398
  • [5] Apatinib as first-line treatment in patients with advanced hepatocellular carcinoma: a phase II clinical trial
    Hou, Zhenyu
    Zhu, Keyun
    Yang, Xuejiao
    Chen, Ping
    Zhang, Wei
    Cui, Yunlong
    Zhu, Xiaolin
    Song, Tianqiang
    Li, Qiang
    Li, Huikai
    Zhang, Ti
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (17)
  • [6] Quality of Life with Nivolumab and AVD First-Line Treatment in Hodgkin Lymphoma: Patient-Reported Outcomes from the Phase II GHSG NIVAHL Trial
    Broeckelmann, Paul J.
    Buehnen, Ina
    Herhaus, Peter
    Meissner, Julia
    Trautmann, Karolin
    Mueller, Horst
    Fuchs, Michael
    von Tresckow, Bastian
    Borchmann, Peter
    Engert, Andreas
    Behringer, Karolin
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 115 - 115
  • [7] Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group
    Eichenauer, Dennis A.
    Pluetschow, Annette
    Kreissl, Stefanie
    Soekler, Martin
    Hellmuth, Johannes C.
    Meissner, Julia
    Mathas, Stephan
    Topp, Max S.
    Behringer, Karolin
    Klapper, Wolfram
    Kuhnert, Georg
    Dietlein, Markus
    Kobe, Carsten
    Fuchs, Michael
    Diehl, Volker
    Engert, Andreas
    Borchmann, Peter
    LANCET ONCOLOGY, 2017, 18 (12): : 1680 - 1687
  • [8] Clinical Observation of Camrelizumab (CAM) Combined with Bendamustine and Gemcitabine (BeGe) in Relapsed/Refractory Classical Hodgkin Lymphoma (cHL): A Phase II Trial
    Bai, Min
    Su, Li-Ping
    Guan, Tao
    BLOOD, 2023, 142
  • [9] Phase II Trial of XELOX as First-Line Treatment for Patients with Advanced Gastric Cancer
    Luo, Hui-yan
    Xu, Rui-hua
    Wang, Feng
    Qiu, Miao-zhen
    Li, Yu-hong
    Li, Fang-hua
    Zhou, Zhi-wei
    Chen, Xiao-qin
    CHEMOTHERAPY, 2010, 56 (02) : 94 - 100
  • [10] Phase III study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A plus AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma (HL).
    Younes, Anas
    Radford, John
    Ansell, Stephen Maxted
    Gallamini, Andrea
    Kim, Wom Seog
    Feldman, Tatyana A.
    Hamadani, Mehdi
    Chung, Jeanenne
    Wang, Jingyuan
    Huebner, Dirk
    Connors, Joseph M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345